Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Indicators
Acorda Therapeutics, Inc. (NQ: ACOR)
34.84 USD  -0.11 (-0.31%)
Official Closing Price  /  Updated: 4:00 PM EDT, Jun 19, 2013  /  Add to My Watchlist      
View: Quote News Research
Press releases about Acorda Therapeutics, Inc.
 
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
New Memoir by Singer/Songwriter Kristie Salerno Kent Follows Her Journey as a Multiple Sclerosis Patient Advocate
May 29, 2013
from Business Wire News Releases
Acorda to Present New Research on AMPYRA® at Fifth Cooperative Meeting of CMSC and ACTRIMS
May 28, 2013
from Business Wire News Releases
CORRECTING and REPLACING Acorda Therapeutics Announces Publication of New Data on Impact of Mobility Impairment Due to Multiple Sclerosis
May 21, 2013
from Business Wire News Releases
Acorda Therapeutics Announces Issuance of Additional U.S. Patent for AMPYRA® Covering a Range of Dosage Strengths
May 20, 2013
from Business Wire News Releases
Acorda Therapeutics’ Legal Department Recognized on Best Legal Departments List by Corporate Counsel Magazine
May 17, 2013
from Business Wire News Releases
Acorda Therapeutics to Present at the UBS Global Healthcare Conference
May 15, 2013
from Business Wire News Releases
Acorda Therapeutics to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
May 09, 2013
from Business Wire News Releases
Acorda Therapeutics Announces Data Showing Dalfampridine Improves Motor Function in Preclinical Model of Post-Stroke Deficits Published in Stroke
May 09, 2013
from Business Wire News Releases
Acorda Therapeutics Recognized as One of the Best Places to Work in New York State for Third Consecutive Year
May 06, 2013
from Business Wire News Releases
Acorda Therapeutics Reports First Quarter 2013 Financial Results
May 02, 2013
from Business Wire News Releases
Acorda Therapeutics to Host Conference Call to Discuss First Quarter 2013 Financial Results on May 2, 2013
April 25, 2013
from Business Wire News Releases
Mayo Clinic and Acorda Therapeutics Announce Initiation of Phase 1 Trial of Remyelinating Antibody in People with Multiple Sclerosis
April 23, 2013
from Business Wire News Releases
Free Research Reports on ACI, ACOR, C and NEM Issued by the Bedford Report
April 16, 2013
Note to Editors: The Following Is an Investment Opinion Being Issued by the EQUITY NEWS CIRCUIT Read More
from Marketwired News Releases
Acorda Therapeutics Announces Positive AMPYRA® (dalfampridine) Phase 2 Data in People with Post-Stroke Deficits
April 15, 2013
from Business Wire News Releases
Diazepam Nasal Spray Demonstrates Comparable Bioavailability to Diazepam Rectal Gel in Pharmacokinetic Study
March 20, 2013
from Business Wire News Releases
Acorda to Present New Research on Novel Multiple Sclerosis and Epilepsy Therapies at American Academy of Neurology 65th Annual Meeting
March 13, 2013
from Business Wire News Releases
Data from First Clinical Trial of GGF2 in Heart Failure Presented at the American College of Cardiology 62nd Annual Scientific Session
March 07, 2013
from Business Wire News Releases
Biogen Idec presenta nuevos datos sobre sus diversas carteras neurológicas durante el 65º Congreso Anual de la AAN
March 07, 2013
from Business Wire Spanish
Biogen Idec to Present New Data on Diverse Neurological Portfolio at 65th AAN Annual Meeting
March 06, 2013
from Business Wire News Releases
Acorda Therapeutics to Present at the Cowen & Company 33rd Annual Health Care Conference
February 25, 2013
from Business Wire News Releases
Acorda Therapeutics to Present at RBC Capital Markets and Citi 2013 Global Healthcare Conferences
February 19, 2013
from Business Wire News Releases
Acorda Therapeutics Announces Company Intranet Named One of Ten Best in the World
February 14, 2013
from Business Wire News Releases
Acorda Therapeutics Reports Fourth Quarter and Full Year 2012 Financial Results
February 13, 2013
from Business Wire News Releases
Acorda Therapeutics to Present at Leerink Swann Global Healthcare Conference
February 07, 2013
from Business Wire News Releases
Acorda Therapeutics Presents GGF2 Preclinical Stroke Data at International Stroke Conference
February 07, 2013
from Business Wire News Releases
Acorda Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year 2012 Financial Results on February 13, 2013
February 06, 2013
from Business Wire News Releases
Free Research Report on ABIOMED, Inc., Acco Brands Corp., Acorda Therapeutics, Inc., Addus HomeCare Corp and First Majestic Silver Corp.
January 31, 2013
from PR Newswire
Acorda Therapeutics Announces Department of Defense Contract to Support Study of AC105 in Acute Spinal Cord Injury
January 24, 2013
from Business Wire News Releases
Acorda Therapeutics Provides Corporate Update at 31st Annual J.P. Morgan Healthcare Conference
January 07, 2013
from Business Wire News Releases
Biotech Industry Experiencing More FDA New Drug Approvals in 2012
January 04, 2013
Five Star Equities Provides Stock Research on Acorda Therapeutics and Peregrine Pharmaceuticals Read More
from Marketwired News Releases
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here